About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company based in Mumbai, Maharashtra, India. Founded by Mr. Gracias Saldanha in 1977, the company manufactures and sells finished branded formulations, generic drugs and active pharmaceutical ingredients (APIs) in 80+ countries including India, the United States, EU, Japan and South America.


According to SCRIP 100 Rankings (2014), Glenmark was ranked among the world’s top 80 pharma and biotech companies in terms of revenues.


The company’s US subsidiary (Glenmark Generics Inc.) is one of the Top 25 generic drug companies in the US, with portfolio of 90+ products in niche segments like dermatology, hormones, controlled substances, oncology, and modified release products, and has nearly 70 ANDAs pending for approval with the USFDA.


Glenmark’s primary business:

  • is structured around drug discovery, branded formulations, generics formulations and active pharmaceutical ingredients (APIs)
  • covers areas such as dermatology, internal medicine, paediatrics, cardiovascular, gynaecology, anti-infectives, antibiotics, anti-allergics, anti-emetics, ENT, diabetes, etc.


The company has:


  • 18 manufacturing plants (8 USFDA approved), comprising:
    • 12 finished dosage plants in 6 countries
    • 5 API plants in India for captive and commercial requirements
    • 1 GMP-grade biologics manufacturing plant in Switzerland
  • 6 R&D centers
  • 20 offices worldwide


Glenmark acquired the following companies since 2004:

  • Klinger Laboratories, Brazil (2004)
  • Bouwer Bartlett Pty. Ltd. (2006)
  • Servycal S. A. (Servycal), Argentina (2006)
  • Medicamenta, Czech Republic (2007)
  • Seven Brands, Poland (2008)


Glenmark Pharmaceuticals Limited is listed in both Bombay Stock Exchange and National Stock Exchange.


Glenmark Pharmaceuticals Limited at-a-glance


  • Employees 11,500+
  • Sales Turnover USD1.08 Bn
  • Markets Served 80+
  • Manufacturing Facilities 18
  • R&D Centers 6
  • Global Offices (countries) 20


*Source: http://www.glenmarkpharma.com/

Certifications US-FDA



TPD (Canada)

MCC (South Africa)

ANVISA (Brazil)

OHSAS 18001:2007

ISO 14001:2004


History of Glenmark Pharmaceuticals Ltd.


The company has not shared this information



  • 1977 – 1980

    • 1977 – Incorporated under the companies act as Glenmark Pharmaceuticals Limited

    • 1979 – Launches ‘Candid Cream’, a dermatology product; breaks even and records a small profit.

    • 1980 – Starts its export business

  • 1981 – 1989

    • 1981 – Sales cross INR 1 Crore (INR 10 million)

    • 1988 – Commissions the first manufacturing facility at Nasik, Maharashtra

    • 1984 – Establishes R&D division at Nasik plant

    • 1987 – Launches Ascoril

    • 1989 – Starts operations in Afghanistan, Sri Lanka, Kenya and Mauritius

  • 1990 – 1999

    • 1992 – Expands Nasik Plant and increases installed capacity

    • 1996 – Incorporates Glenmark Exports Private limited, a wholly owned subsidiary, to consolidate its position in international business

    • 1999 – Starts marketing products in Brazil


– Commissions R&D facility at Nasik, Maharashtra for developing formulations


  • 2000 – 2010

    • 2000

      • Announces IPO (oversubscribed by a factor of 65)

      • Enters the diabetes segment

      • Acquires 3 brands from Lyka Labs

    • 2001 – Launches first manufacturing facility for APIs in Kurkumbh, Maharashtra

    • 2002 – Acquires an API manufacturing facility from GlaxoSmithKline Pharmaceuticals Ltd. at Ankleshwar, Gujarat

    • 2004

      • Strikes first out-licensing deal for discovery R&D with Forest Laboratories for Oglemilast, its COPD/asthma molecule

      • Acquires Laboratorios Klinger, Brazil together with its ANVISA approved manufacturing facility to expand Latin American operations

      • Commissions manufacturing facility at Goa export to regulated markets, like USA

      • Commissions API manufacturing facility in Mohol, Maharashtra

    • 2005

      • Launches front–end commercial sales in the US

      • Enters into collaborative agreement on Oglemilast with Teijin Pharma for the Japan region

      • Announces collaborative agreement with Napo Pharmaceuticals Inc. for anti–diarrheal compound, Crofelemer with rights in nearly 140 countries

      • Acquires Servycal S.A, a marketing company in Argentina (oncology)

      • Acquires Bouwer Bartlett Pty., Ltd., a sales and marketing company in South Africa

      • Commissions a new manufacturing facility at Baddi, Himachal Pradesh

    • 2006

      • Signs another outlicensing deal in discovery R&D with Merck KGaA, Germany for its diabetes molecule, Melogliptin and receives USD 31 million as upfront payment

      • Receives milestone payment from Forest Laboratories Inc. for successful completion of Phase I trials

      • Commissions R&D facility for NBE research in Switzerland

    • 2007

      • Acquires Medicamenta, a marketing and manufacturing company in the Czech Republic

      • Concludes deal with Paul Capital to license and market generic drugs for the US market via US subsidiary

      • Outlicenses GRC 6211 molecule for pain treatment to Eli Lily and receives USD 45 million as upfront payment

      • Wins Emerging Company of The Year 2007 at The Economic Times Awards for Corporate Excellence

      • Receives MHRA, UK approval for its semi-solid manufacturing plant at Baddi

    • 2008

      • Receives fast-track status from the USFDA for Crofelemer

      • Named "Best Pharma Company in the World – SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London

      • Sets up clinical R&D facility in Oxford, UK (India’s first)

      • Receives USD 15 million as milestone payment from Forest for Oglemilast, GRC 3886

      • Reorganizes business and incorporates Glenmark Generics Limited (GGL) as a subsidiary of Glenmark Pharmaceuticals Limited

      • Receives USFDA approval for semi–solids manufacturing plant at Baddi, Himachal Pradesh

    • 2009

      • Commissions formulations manufacturing facility at Nalagarh, Himachal Pradesh

      • Commissions first exclusive R&D Center at Taloja, Maharashtra, India

    • 2000 – 2010

      • Launches ‘Prasugrel’ – a revolutionary new anti-platelet drug for the managing Acute Coronary Syndrome with PCI (Percutaneous Coronary Intervention) for the first time in India

      • Signs license agreement with Sanofi-Aventis allowing the latter to develop and commercialize novel agents to treat chronic pain

      • Enters into an exclusive licensing agreement with Par Pharmaceuticals, USA to market Ezetimibe

      • Announces the discovery of a novel chemical entity ‘GRC 17536’

      • Receives the final approval for Pramipexole Dihydrochloride tablets from the USFDA

      • Wins the Frost and Sullivan award for 'Indian Innovator Pharmaceutical Company of the Year' in October 2010

      • Receives the ‘Silver Patent Award’ for the year 2009 – 2010 from Pharmaexcil for commendable contribution in NCE / Drug Discovery patent category

      • Successfuly completes Phase 3 trials for Crofelemer, a first-in-class anti-diarrhoeal molecule and prepares for launch in 140 countries

    • 2011

      • Wins Two Prestigious Global Recognitions at SCRIP Awards 2011 – 'Best Company in Emerging Markets' and 'Best Overall Pipeline'

      • Out-Licenses Novel Monoclonal Antibody, GBR 500, to Sanofi

    • 2012

      • Founder & Chairman Emeritus, Mr. Gracias Saldanha, passes away peacefully in Mumbai

      • Mr. Glenn Saldanha, Chairman & Managing Director, honored with the 'Swiss Ambassador's Award for Exceptional Innovation' by the Government of Switzerland

      • Enters into an options agreement with Forest Laboratories, Inc. to develop novel mPGES-1 inhibitors for treating chronic inflammatory conditions, including pain



  • Founder: Mr. Gracias Saldanha

  • Chairman & Managing Director: Mr. Glenn Saldanha

  • Executive Director: Mr. Rajesh Desai

  • Director – Corporate Affairs Mrs. Cherylann Pinto

  • Non-Executive Promoter Group Mrs. B. E. Saldanha

  • Non-Executive Independent Directors Mr. DR Mehta, Mr. Bernard Munos, Mr. JF Ribeiro, Dr. Brian W Tempest, Mr. Sridhar Gorthi, Mr. NB Desai, Mr. Hocine Sidi Said


Glenmark Pharmaceuticals Contact Details:



Glenmark Pharmaceuticals Limited

Glenmark House

HDO – Corporate Building, Wing A

BD Sawant Marg, Chakala

Off Western Express Highway

Andheri (East), Mumbai – 400099


Tel: +91 22 40189999

E-mail: complianceofficer@glenmarkpharma.com

Website: http://www.glenmarkpharma.com/



Glenmark Pharmaceuticals Inc., USA

750 Corporate Drive

Mahwah NJ 07430


Tel: +1 201 684 8033

Fax: +1 201 831 0080

E-mail: uspai.web@glenmarkpharma.com








E-mail: corpcomm@glenmarkpharma.com











Glenmark Pharmaceuticals Europe Ltd.

Building 2, Croxley Green Business Park

Marlins Meadow, Watford

WD18 8YA



Tel: +44 (0) 1923 202 950

Fax: +44 (0) 1923 236 692

E-mail: euapi.web@glenmarkpharma.com


Glenmark Pharmaceuticals Ltd.

Glenmark House, HDO Corporate Building,

A-Wing, B. D. Sawant Marg,

Off W. E. Highway,

Chakala, Andheri (East),

Mumbai 400099



Tel: +91 22 40189681

Fax: +91 22 40189989

E-mail: jaapi.web@glenmarkpharma.com


Glenmark Farmacêutica Ltda.

Rua Frei Liberato de Gries, 548 Jardim Arpoador

São Paulo – SP

Brazil 05572-210


Tel: +55 11 5504 2770

Fax: +55 11 5504 2717

E-mail: laapi.web@glenmarkpharma.com





* Indicates mandatory field.
Please wait while comments are being sent...